Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Pfizer has now announced that it intends to sell Comirnaty for between $110 and $130 per dose – roughly four times the current price, and 100 times The People’s Vaccine Alliance’s estimated ...

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Pfizer reported higher-than-expected profit on Tuesday due to strong sales of COVID-19 treatment Paxlovid, an important win ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Anticipated revenues for Comirnaty and Paxlovid, approximately $5 billion and $5.5 billion in 2024. Pfizer expects full-year 2024 operational revenue growth of 9% to 11% compared to 2023 revenue.

Amid a share value slump and executive turmoil, Pfizer reported a robust quarter, thanks in part to Covid-19 drug sales.

Pfizer (NYSE: PFE) is in that group, in my opinion. The big drugmaker's forward dividend yield currently stands at just under ...

Including the contribution from Seagen and excluding revenues from Comirnaty and Paxlovid, Pfizer (PFE) continues to expect full-year 2024 operational revenue growth of 9% to 11% compared to 2023 ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

COVID-19 Product Revenue Guidance: $10.5 billion ($5 billion for COMIRNATY and $5.5 billion for Paxlovid). Full-Year Adjusted Diluted EPS Guidance: $2.75 to $2.95. Pfizer Inc (NYSE:PFE ...